- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04552067
Enoxaparin Bioequivalence Study in Acute Coronary Syndrome Patients (Enoxaparine)
Generic and Branded Enoxaparin Bioequivalence: a Randomized Study in Acute Coronary Syndrome Patients With an In-vitro Thrombin Generation Testing Comparison
Because of their anti-Xa and ease of administration activity, the Low molecular weight heparin represent an attractive alternative to the unfractionated heparin. Several clinical trials have demonstrated that Low molecular weight heparin was more effective than Unfractionated heparin without increasing bleeding complications. Enoxaparin has been the most studied. Its use is recommended.
Demonstrate that Enoxa® is comparable to that of Lovenox® in the anti-Xa activity action.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Single-center randomized controlled trial, single-blind, including patient with an acute coronary syndrome confirmed, to measure the anti-Xa activity between H0 and H4.the study was done on two groups ; ENOXA® group : In this case the patient is given an injection of enoxaparin ( ENOXA® ; UNIMED Laboratories) intravenously. Curative dose (100 IU/10 kg).
Control group ( LOVENOX ® ):
In this case the patient receives LOVENOX intravenous injection curative dose of 100 kg IU/10 .
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Monastir, Tunisia, 5000
- Emergency Department of University Hospital of Monastir
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age over 18 year old
- With an acute coronary syndrome confirmed
Exclusion Criteria:
- Age less than 18 years
- Persistent ST segment elevation
- Contre indication of enoxaparin and heparin in general.
- Patient participating in another study,
- Pregnant or nursing women
- patients taking an anticoagulant in the last three months,
- Patients with coagulopathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: LOVENOX
patients are given a curative dose of Enoxaparin (LOVENOX)
|
patients given curative dose of Lovenox
|
Active Comparator: Enoxamed
patients are given a curative dose of Enoxaparin (ENOXA)
|
patients given curative dose of Enoxa
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
anti Xa activity (UI/ml)
Time Frame: 4 hours
|
Compare the Anticoagulant Activity (measured in a UI per ml in a reference laboratory) of Two Formulations of Enoxaparin [ENOXA ® Versus LOVENOX ®], Conducted on Two Parallel Groups of Patients Admitted to Emergency for Acute Coronary Syndrome
|
4 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Adverse Cardiac Events
Time Frame: 30 days
|
All major cardiovascular events
|
30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Enoxaparine
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Yonsei UniversityCompletedAcute Coronary Syndrome (ACS)Korea, Republic of
Clinical Trials on Lovenox
-
Oregon Health and Science UniversityNational Trauma Research Institute; Medical Research Foundation, OregonCompleted
-
Columbia UniversityCompletedCOVID-19 | Venous Thromboses | Arterial ThrombosisUnited States
-
Brigham and Women's HospitalSanofiCompletedDeep Vein Thrombosis | Pulmonary EmbolismUnited States
-
University Hospital, BrestCompletedVenous ThromboembolismFrance, Switzerland
-
Dana-Farber Cancer InstituteNational Heart, Lung, and Blood Institute (NHLBI)CompletedVenous ThormboembolismUnited States
-
Yale UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedDeep Venous ThrombosisUnited States
-
University of UtahCompletedThrombosis | Thromboembolism | Postpartum DVTUnited States
-
MemorialCare Health SystemCompletedObesity | Pregnancy | Venous Thromboembolism | Obesity, Morbid | Pulmonary Embolism | Complications; Cesarean Section | Postpartum Deep PhlebothrombosisUnited States
-
NorthShore University HealthSystemRecruitingAdverse Pregnancy OutcomeUnited States